TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient
Open Access
- 19 June 2019
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 11 (6) , e4946
Abstract
Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder that manifests as multiorgan dysfunction secondary to widespread inflammation. The underlying pathogenesis is driven by an excessive and inappropriate cytokine storm. TAFRO syndrome is a rare subtype of iMCD, characterized by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly. Multiorgan dysfunction is a known consequence of this syndrome, although endocrine involvement has yet to be reported. We present a case of TAFRO in a previously healthy Caucasian male who presented with abdominal pain, dysuria, diffuse anasarca, and ascites. On presentation, the patient was found to have acute kidney injury, thrombocytopenia, elevated inflammatory markers, elevated interleukin-6 (IL-6), and endocrinopathy. Following an extensive infectious and autoimmune workup, lymph node biopsy confirmed the diagnosis of TAFRO. The patient was started on prednisone, rituximab, and anti-IL-6 therapy with siltuximab. He achieved clinical remission after 4 months of treatment, with normalization of renal function, thrombocytopenia, inflammatory markers, and endocrinopathy. He has continued on siltuximab for maintenance therapy. It is our hope that this unique case of TAFRO syndrome with significant endocrinopathy will add to the growing literature surrounding iMCD, and help clinicians better understand the pathogenesis and treatment of this rare disease.Keywords
This publication has 10 references indexed in Scilit:
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman diseaseBlood, 2018
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseBlood, 2018
- Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplementsClinical Case Reports, 2018
- TAFRO syndrome: current perspectivesJournal of Blood Medicine, 2018
- A comparison of TAFRO syndrome between Japanese and non-Japanese cases: a case report and literature reviewAnnals of Hematology, 2017
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017
- Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous HemodiafiltrationFrontiers in Medicine, 2017
- Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman diseaseAmerican Journal of Hematology, 2015
- Endocrinopathy in POEMS Syndrome: The Mayo Clinic ExperienceMayo Clinic Proceedings, 2007
- POEMS syndrome: definitions and long-term outcomeBlood, 2003